#BEGIN_DRUGCARD DB07726

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C10H14O2

# Chemical_IUPAC_Name:
2-tert-butylbenzene-1,4-diol

# Chemical_Structure:
Not Available

# Creation_Date:
2010-09-15 15:25:17 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
2-tert-butylbenzene-1,4-diol

# HET_ID:
EYK

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C10H14O2/c1-10(2,3)8-6-7(11)4-5-9(8)12/h4-6,11-12H,1-3H3

# InChI_Key:
InChIKey=BGNXCDMCOKJUMV-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
7732

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
166.217

# Molecular_Weight_Mono:
166.099379692

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
2.61

# Predicted_LogS:
-1.8

# Predicted_Water_Solubility:
2.75e+00 g/l

# Primary_Accession_No:
DB07726

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
16043

# PubChem_Substance_ID:
99444197

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(C)(C)C1=CC(O)=CC=C1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:25:58 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Virion membrane

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_1_Essentiality:
Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
M35996

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
HA

# Drug_Target_1_Gene_Name:
Not Available

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Involved in host cell surface receptor binding

# Drug_Target_1_General_References:
2238469	Kawaoka Y, Yamnikova S, Chambers TM, Lvov DK, Webster RG: Molecular characterization of a new hemagglutinin, subtype H14, of influenza A virus. Virology. 1990 Dec;179(2):759-67.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
6566

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
62590.1

# Drug_Target_1_Name:
Hemagglutinin

# Drug_Target_1_Number_of_Residues:
563

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00509	Hemagglutinin

# Drug_Target_1_Protein_Sequence:
>Hemagglutinin
LVALALSQTAYSQITNGTTGNPIICLGHHAVENGTSVKTLTDNHVEVVSAKELVETKHTD
ELCPSPLKLVDGQDCDLINGALGSPGCDRLQDTTWDVFIERPTAVDTCYPFDVPDYQSLR
SILASSGSLEFIAEQFTWNGVKVDGSSSACLRGGRNSFFSRLNWLTKATNGNYGPINVTK
ENTGSYVRLYLWGVHHPSSDNEQTDLYKVATGRVTVSTRSDQISIVPNIGSRPRVRNQSG
RISIYWTLVNPGDSIIFNSIGNLIAPRGHYKISKSTKSTVLKSDKRIGSCTSPCLTDKGS
IQSDKPFQNVSRIAIGNCPKYVKQGSLMLATGMRNIPGKQAKGLFGAIAGFIENGWQGLI
DGWYGFRHQNAEGTGTAADLKSTQAAIDQINGKLNRLIEKTNEKYHQIEKEFEQVEGRIQ
DLEKYVEDTKIDLWSYNAELLVALENQHTIDVTDSEMNKLFERVRRQLRENAEDQGNGCF
EIFHQCDNNCIESIRNGTYDHNIYRDEAINNRIKINPVTLTMGYKDIILWISFSMSCFVF
VALILGFVLWACQNGNIRCQICI

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-12

# Drug_Target_1_Specific_Function:
Binds to sialic acid-containing receptors on the cell surface, bringing about the attachment of the virus particle to the cell. Plays a major role in the determination of host range restriction and virulence. Class I viral fusion protein. Responsible for penetration of the virus into the cell cytoplasm by mediating the fusion of the membrane of the endocytosed virus particle with the endosomal membrane. Low pH in endosomes induce an irreversible conformational change in HA2, releasing the fusion hydrophobic peptide. Several trimers are required to form a competent fusion pore

# Drug_Target_1_SwissProt_ID:
P26137

# Drug_Target_1_SwissProt_Name:
HEMA_I82A0HA

# Drug_Target_1_Synonyms:
Fragment
Hemagglutinin HA1 chain
Hemagglutinin HA2 chain

# Drug_Target_1_Theoretical_pI:
6.77

# Drug_Target_1_Transmembrane_Regions:
527-547

# Drug_Target_2_Cellular_Location:
Cell membrane

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
J02090

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
HA

# Drug_Target_2_Gene_Sequence:
>1701 bp
ATGAAGACCATCATTGCTTTGAGCTACATTTTCTGTCTGGCTCTCGGCCAAGACCTTCCA
GGAAATGACAACAGCACAGCAACGCTGTGCCTGGGACATCATGCGGTGCCAAACGGAACA
CTAGTGAAAACAATCACAGATGATCAGATTGAAGTGACTAATGCTACTGAGCTAGTTCAG
AGCTCCTCAACGGGGAAAATATGCAACAATCCTCATCGAATCCTTGATGGAATAGACTGC
ACACTGATAGATGCTCTATTGGGGGACCCTCATTGTGATGTTTTTCAAAATGAGACATGG
GACCTTTTCGTTGAACGCAGCAAAGCTTTCAGCAACTGTTACCCTTATGATGTGCCAGAT
TATGCCTCCCTTAGGTCACTAGTTGCCTCGTCAGGCACTCTGGAGTTTATCACTGAGGGT
TTCACTTGGACTGGGGTCACTCAGAATGGGGGAAGCAATGCTTGCAAAAGGGGACCTGGT
AGCGGTTTTTTCAGTAGACTGAACTGGTTGACCAAATCAGGAAGCACATATCCAGTGCTG
AACGTGACTATGCCAAACAATGACAATTTTGACAAACTATACATTTGGGGGATTCACCAC
CCGAGCACGAACCAAGAACAAACCAGCCTGTATGTTCAAGCATCAGGGAGAGTCACAGTC
TCTACCAGGAGAAGCCAGCAAACTATAATCCCGAATATCGGGTCCAGACCCTGGGTAAGG
GGTCTGTCTAGTAGAATAAGCATCTATTGGACAATAGTTAAGCCGGGAGACGTACTGGTA
ATTAATAGTAATGGGAACCTAATCGCTCCTCGGGGTTATTTCAAAATGCGCACTGGGAAA
AGCTCAATAATGAGGTCAGATGCACCTATTGATACCTGTATTTCTGAATGCATCACTCCA
AATGGAAGCATTCCCAATGACAAGCCCTTTCAAAACGTAAACAAGATCACATATGGAGCA
TGCCCCAAGTATGTTAAGCAAAACACCCTGAAGTTGGCAACAGGGATGCGGAATGTACCA
GAGAAACAAACTAGAGGCCTATTCGGCGCAATAGCAGGTTTCATAGAAAATGGTTGGGAG
GGAATGATAGACGGTTGGTACGGTTTCAGGCATCAAAATTCTGAGGGCACAGGACAAGCA
GCAGATCTTAAAAGCACTCAAGCAGCCATCGACCAAATCAATGGGAAATTGAACAGGGTA
ATCGAGAAGACGAACGAGAAATTCCATCAAATCGAAAAGGAATTCTCAGAAGTAGAAGGG
AGAATTCAGGACCTCGAGAAATACGTTGAAGACACTAAAATAGATCTCTGGTCTTACAAT
GCGGAGCTTCTTGTCGCTCTGGAGAATCAACATACAATTGACCTGACTGACTCGGAAATG
AACAAGCTGTTTGAAAAAACAAGGAGGCAACTGAGGGAAAATGCTGAAGAGATGGGCAAT
GGTTGCTTCAAAATATACCACAAATGTGACAACGCTTGCATAGAGTCAATCAGAAATGGT
ACTTATGACCATGATGTATACAGAGACGAAGCATTAAACAACCGGTTTCAGATCAAAGGT
GTTGAACTGAAGTCTGGATACAAAGACTGGATCCTGTGGATTTCCTTTGCCATATCATGC
TTTTTGCTTTGTGTTGTTTTGCTGGGGTTCATCATGTGGGCCTGCCAGAGAGGCAACATT
AGGTGCAACATTTGCATTTGA

# Drug_Target_2_General_Function:
Involved in host cell surface receptor binding

# Drug_Target_2_General_References:
2295311	Weis WI, Cusack SC, Brown JH, Daniels RS, Skehel JJ, Wiley DC: The structure of a membrane fusion mutant of the influenza virus haemagglutinin. EMBO J. 1990 Jan;9(1):17-24.
2329580	Weis WI, Brunger AT, Skehel JJ, Wiley DC: Refinement of the influenza virus hemagglutinin by simulated annealing. J Mol Biol. 1990 Apr 20;212(4):737-61.
3374584	Weis W, Brown JH, Cusack S, Paulson JC, Skehel JJ, Wiley DC: Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature. 1988 Jun 2;333(6172):426-31.
7402351	Verhoeyen M, Fang R, Jou WM, Devos R, Huylebroeck D, Saman E, Fiers W: Antigenic drift between the haemagglutinin of the Hong Kong influenza strains A/Aichi/2/68 and A/Victoria/3/75. Nature. 1980 Aug 21;286(5775):771-6.
7464906	Wilson IA, Skehel JJ, Wiley DC: Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature. 1981 Jan 29;289(5796):366-73.
8072525	Bullough PA, Hughson FM, Skehel JJ, Wiley DC: Structure of influenza haemagglutinin at the pH of membrane fusion. Nature. 1994 Sep 1;371(6492):37-43.
9461077	Fleury D, Wharton SA, Skehel JJ, Knossow M, Bizebard T: Antigen distortion allows influenza virus to escape neutralization. Nat Struct Biol. 1998 Feb;5(2):119-23.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
4890

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
63416

# Drug_Target_2_Name:
Hemagglutinin

# Drug_Target_2_Number_of_Residues:
566

# Drug_Target_2_PDB_ID:
1HA0

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00509	Hemagglutinin

# Drug_Target_2_Protein_Sequence:
>Hemagglutinin
MKTIIALSYIFCLALGQDLPGNDNSTATLCLGHHAVPNGTLVKTITDDQIEVTNATELVQ
SSSTGKICNNPHRILDGIDCTLIDALLGDPHCDVFQNETWDLFVERSKAFSNCYPYDVPD
YASLRSLVASSGTLEFITEGFTWTGVTQNGGSNACKRGPGSGFFSRLNWLTKSGSTYPVL
NVTMPNNDNFDKLYIWGIHHPSTNQEQTSLYVQASGRVTVSTRRSQQTIIPNIGSRPWVR
GLSSRISIYWTIVKPGDVLVINSNGNLIAPRGYFKMRTGKSSIMRSDAPIDTCISECITP
NGSIPNDKPFQNVNKITYGACPKYVKQNTLKLATGMRNVPEKQTRGLFGAIAGFIENGWE
GMIDGWYGFRHQNSEGTGQAADLKSTQAAIDQINGKLNRVIEKTNEKFHQIEKEFSEVEG
RIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEMNKLFEKTRRQLRENAEEMGN
GCFKIYHKCDNACIESIRNGTYDHDVYRDEALNNRFQIKGVELKSGYKDWILWISFAISC
FLLCVVLLGFIMWACQRGNIRCNICI

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
1-16

# Drug_Target_2_Specific_Function:
Binds to sialic acid-containing receptors on the cell surface, bringing about the attachment of the virus particle to the cell. Plays a major role in the determination of host range restriction and virulence. Class I viral fusion protein. Responsible for penetration of the virus into the cell cytoplasm by mediating the fusion of the membrane of the endocytosed virus particle with the endosomal membrane. Low pH in endosomes induce an irreversible conformational change in HA2, releasing the fusion hydrophobic peptide. Several trimers are required to form a competent fusion pore

# Drug_Target_2_SwissProt_ID:
P03437

# Drug_Target_2_SwissProt_Name:
HEMA_I68A0

# Drug_Target_2_Synonyms:
Hemagglutinin precursor

# Drug_Target_2_Theoretical_pI:
6.71

# Drug_Target_2_Transmembrane_Regions:
531-551

#END_DRUGCARD DB07726
